INS and liver cancer: Compared with observation, meta-analysis of the direct comparisons showed that the use of metformin (RR 0.49, 95% CI 0.25–0.97) was associated with a significant risk reduction of HCC, while insulin (RR 2.44, 95% CI 1.10–5.56) appeared to increase the risk of liver cancer.